Synapse - Mark Kris

Results (39)

Outcomes after radiation for oligoprogressive disease sites in patients with EGFR-mutant lung cancer treated with osimertinib

Journal Article

Chen, M. F.; Jeng, M. Y.; Ma, J.; Agrawal, P.; Dunne, E.; Boe, L. A.; Kris, M. G.; Huang, J.; Veeraraghavan, H.; Gomez, D.; more...
JCO Precision Oncology (2025)

Fulltext@MSK | Save

Next-generation sequencing for HLA genotype screening and matching to HLA-restricted therapies

Research Letter

Gormally, M. V.; Chen, M. F.; Noronha, A. M.; Panageas, K.; Reynolds, M.; Kohlasch, K.; Novak, B.; Kee-Velez, T.; Clarke, N.; Eubank, M.; more...
JAMA Oncology (2025)

Fulltext@MSK | Save

Targeting TROP-2 in diffuse pleural mesothelioma

Meeting Abstract

Offin, M. D.; Tischfield, S.; Manoj, P.; Agrawal, P.; Tendler, S.; Pratt, E. C.; Travis, W.; Rimner, A.; Simone, C. B.; de Stanchina, E.; more...
Journal of Thoracic Oncology (2024)

Fulltext@MSK | Save

Tumor-agnostic genomic and clinical analysis of BRAF fusions identifies actionable targets

Journal Article

Chen, M. F.; Yang, S. R.; Tao, J. J.; Desilets, A.; Diamond, E. L.; Wilhelm, C.; Rosen, E.; Gong, Y.; Mullaney, K.; Torrisi, J.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease

Meeting Abstract

Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: Results of a prospective pilot study

Meeting Abstract

Offin, M.; Lavin, Y.; Zatzman, M.; Sauter, J. L.; Ceglia, N.; Travis, W. D.; Aly, R. G.; Rimner, A.; Shepherd, A.; Simone, C. B. 2nd; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations

Meeting Abstract

Chen, M. F.; Rakhade, S.; Quintanal-Villalonga, A.; Lee, J.; Forsythe, B.; Moses, K. A.; Ahn, L. S. H.; Pupo, A.; Falcon, C. J.; Rekhtman, N.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer

Journal Article

Liu, S. Y.; Erazo, T.; Jee, J.; Arfe, A.; Gupta, A.; Pike, L. R. G.; Santini, F. C.; Daly, B.; Schoenfeld, A.; Eichholz, J.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

Brief report: Tyrosine kinase inhibitors for lung cancers that inhibit MATE-1 can lead to “false” decreases in renal function

Journal Article

Chen, M. F.; Harada, G.; Liu, D.; DeMatteo, R.; Falcon, C.; Wilhelm, C.; Kris, M. G.; Drilon, A.; Gutgarts, V.
Journal of Thoracic Oncology (2024)

Fulltext@MSK | Save

Response to repotrectinib after development of NTRK resistance mutations on first- and second-generation TRK inhibitors

Journal Article

Chen, M. F.; Yang, S. R.; Shia, J.; Girshman, J.; Punn, S.; Wilhelm, C.; Kris, M. G.; Cocco, E.; Drilon, A.; Raj, N.
JCO Precision Oncology (2023)

Fulltext@MSK | Save